Reduced expression of TRIM21/Ro52 predicts poor prognosis in diffuse large B-cell lymphoma patients with and without rheumatic disease. [electronic resource]
Producer: 20151102Description: 323-32 p. digitalISSN:- 1365-2796
- Aged
- Antibodies, Monoclonal, Murine-Derived -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Biomarkers -- analysis
- Cells, Cultured
- Cyclophosphamide -- therapeutic use
- Doxorubicin -- therapeutic use
- Female
- Humans
- Immunohistochemistry
- In Vitro Techniques
- Lymphoma, Large B-Cell, Diffuse -- drug therapy
- Male
- Prednisolone -- therapeutic use
- Prednisone -- therapeutic use
- Prognosis
- Real-Time Polymerase Chain Reaction
- Rheumatic Diseases -- complications
- Ribonucleoproteins -- analysis
- Rituximab
- Vincristine -- therapeutic use
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.